<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04470453</url>
  </required_header>
  <id_info>
    <org_study_id>19CH114</org_study_id>
    <secondary_id>2019-003700-12</secondary_id>
    <nct_id>NCT04470453</nct_id>
  </id_info>
  <brief_title>Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Biological Drug Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate and a First Biological Drug</brief_title>
  <acronym>POLYbio</acronym>
  <official_title>Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Biological Drug Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate and a First Biological Drug</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of methotrexate (MTX) with a biological disease-modifying antirheumatic drugs
      (bDMARD) is the next step in treatment with MTX monotherapy in rheumatoid arthritis (RA).
      Estimation of MTX and bDMARD impregnation could be performed with the erythrocyte MTX
      polyglutamate (MTX-PG) and bDMARD assays before to move to a second bDMARD. In RA patients
      treated with MTX (prescribed for at least 6 months at a stable dose for at least 3 months) in
      combination to a first bDMARD (prescribed since at least 3 months), an assay of MTX-PG and
      bDMARD will be performed in tow subsets of RA according to the level of disease activity. The
      first subset is active RA defined by a DAS28 (disease activity score 28)&gt;3.2. The second one
      is RA in clinical remission defined by a DAS28&lt;2.6. The main hypothesis is the association
      between the low concentration of MTX-PG and the clinical response of RA patients treated with
      subcutaneous methotrexate injection associated to a first bDMARD. Adherence to MTX will be
      reviewed by the Compliance Questionnaire Rheumatology (CQR) questionnaire. This assay could
      be useful to improve MTX management before to move to a second bDMARD.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTX-PG concentration</measure>
    <time_frame>Hour 1</time_frame>
    <description>To compare MTX-PG concentration in patients with active rheumatoid arthritis and patients with rheumatoid arthritis in remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>metabolites dosing of MTX-PG (nmol/l)</measure>
    <time_frame>Hour 1</time_frame>
    <description>Analysis of different metabolites dosing of MTX-PG by High-performance liquid chromatography technical</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of CQR score response</measure>
    <time_frame>Hour 1</time_frame>
    <description>Compliance Rheumatology Questionnaire (CRQ) is a 19-item self-administered questionnaire to measure overall patient compliance for both MTX and bDMARD treatment with 0 (bad compliance) and 100 (better compliance).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients with active rheumatoid arthritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 patients with active rheumatoid arthritis will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with rheumatoid arthritis into remission</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 patients with rheumatoid arthritis into remission will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood samples will be collected for measuring PG-MTX blood concentration.</description>
    <arm_group_label>Patients with active rheumatoid arthritis</arm_group_label>
    <arm_group_label>Patients with rheumatoid arthritis into remission</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CRQ</intervention_name>
    <description>Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.</description>
    <arm_group_label>Patients with active rheumatoid arthritis</arm_group_label>
    <arm_group_label>Patients with rheumatoid arthritis into remission</arm_group_label>
    <other_name>Compliance Rheumatology Questionnaire</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years and have social security affiliation.

          -  Patients followed in the Rheumatology Department at the hospital of St Etienne.

          -  Rheumatoid Arthritis patients in remission (Disease Activity Score 28&lt;2.6) with
             methotrexate (MTX) treatment for at least 6months, and with a stable dose for 3months.

          -  Patients with a High Disease Activity Rheumatoid Arthritis activity (Disease Activity
             Score 28&gt;3.2) with methotrexate (MTX) treatment (≥ 15 mg/week), taking MTX treatment
             for at least 6months with a stable subcutaneous weekly MTX injection (≥ 15 mg/week)
             treatment during the previous 3 months.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Patients treated with another conventional synthetic Disease Modifying Anti-Rheumatic
             Drugs (csDMARD)

          -  Another diagnostic than rheumatoid arthritis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert MAROTTE, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hubert MAROTTE, MD PhD</last_name>
    <phone>(0)477127643</phone>
    <phone_ext>+33</phone_ext>
    <email>hubert.marotte@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florence RANCON, CRA</last_name>
    <phone>(0)477120284</phone>
    <phone_ext>+33</phone_ext>
    <email>florence.rancon@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Saint Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Hubert MAROTTE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry THOMAS, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Béatrice PALLOT-PRADES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karima BOUSSOUALIM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adamah AMOUZOUGAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Astrid COASSY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Erythrocyte polyglutamate</keyword>
  <keyword>Compliance Questionnaire Rheumatology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

